Gainers on the Previous Trading Session: CZR, ONCY, CLSN, GILD, RTIX

Los Angelas, CA -- (SBWIRE) -- 02/11/2013 -- Caesars Entertainment Corp (NASDAQ:CZR) shares climbed after it declared that its subsidiaries are proposing to issue $1,500.00 million aggregate principal amount of 9% senior secured notes due 2020 (the “Notes”) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). In the last trading session, Caesars Entertainment Corp reported the gain of +38.13% to close at $13.91 and its total traded volume was 9.46 million shares.

Is CZR Showing Any Sign of Buy At The Current Market Price? Find Out Here

Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) shares gained after it declared results observing percent whole tumour reduction data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel. Oncolytics Biotech, Inc. surged +21.85% and closed at $4.35 in the last trading session and its overall traded volume was 8.89 million shares.

Can ONCY Move Up Further? If Yes, How far It can Go? Find Out Here

Celsion Corporation (NASDAQ:CLSN) shares rallied over 11 percent on 7.25 million shares traded Friday. Shares of the company have fallen sharply since reporting ThermoDox did not meet the primary endpoint of the Phase III HEAT Study. Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. As of December 31, 2011, the Company's product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer.

How Should Investors Trade CLSN After The Recent Volatile Moves? Find Out Here

Gilead Sciences, Inc. (NASDAQ:GILD) traded higher on Friday to end the day at $40.90. On February 8, the company declared that it has completed its takeover of YM BioSciences. Pursuant to the deal, YM will now be a wholly-owned subsidiary of Gilead and it is expected that the common equity of YM will no longer be public or listed company to trade on the NYSE MKT LLC or the Toronto Stock Exchange, on or about February 12, 2013.

Can GILD Extend Rally? Find Out Here

RTI Biologics Inc. (NASDAQ:RTIX) plunged 14.98% after forecasting fiscal 2013 revenue in a range of $178-$182 million and net income per fully diluted share of $0.17 to $0.19. For the starting three months of 2013, the Company anticipates revenues of $38 million-$39 million, and net income per fully diluted share to be about $0.02. Analysts, on average, are predicting revenue of $189 million and EPS of $0.22 for fiscal 2013; revenue of $46 million and earnings per share of $0.05 for the first quarter of 2013.

How Should Investors Trade RTIX Now? Find Out Here

DISCLAIMER
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com